Ligand Pharmaceuticals Incorporated

What they do

Ligand invests in and structures royalty interests in mid-to-late-stage and commercial biopharmaceutical products, using transaction types like royalty purchases and development-stage financings. It also operates two infrastructure-light, royalty-generating platform technologies: Captisol, a drug-solubilizing agent, and NITRICIL, a nitric-oxide-releasing technology. Revenue comes primarily from royalties on partner product sales, plus Captisol material sales and contract revenue from license fees and milestones.

Revenue drivers

• Royalties on partner products — Primary revenue source; second quarter 2026 royalties were $48.0 million, up 32% year-over-year, driven by Filspari (Travere), Zelsuvmi (Pelthos), and Ohtuvayre (Merck).
• Captisol material sales — Sales of the Captisol drug-solubilizing material; second quarter 2026 sales were $8.0 million, slightly down from $8.3 million in the prior-year period.
• Contract revenue and income — Includes license fees and milestone payments; second quarter 2026 was $7.7 million, up from $2.9 million, due to timing of milestone events under partner agreements.

Recent performance

For the second quarter of 2026, total revenues and income were $63.7 million, up 34% year-over-year, with GAAP net income of $48.5 million ($2.22 per diluted share) versus $4.8 million ($0.24) in the prior-year period. Adjusted net income was $50.8 million ($2.37 per diluted share), up 59% year-over-year. For the six months ended June 30, 2026, total revenues and income were $115.4 million versus $93.0 million in 2025. Royalty revenue growth was driven by Filspari, Zelsuvmi, and Ohtuvayre, partly offset by higher R&D and G&A expenses, including a $12.3 million R&D funding arrangement with Orchestra BioMed and transaction costs for the XOMA acquisition.

Strategy

Ligand's stated strategy is to aggregate royalty rights in mid-to-late-stage and commercial biopharma products, maintaining a lean infrastructure and high-margin business. The company refocused in 2022 after spinning off OmniAb and Pelican and carving out Pelthos in July 2025. It aims to deploy capital through flexible transaction structures, leveraging partner capabilities to avoid high-cost infrastructure. The company completed a $700 million 0% convertible note offering in June 2026 and closed the XOMA Royalty acquisition in July 2026, adding over 120 assets to diversify its royalty base.

Risks

• Concentration in partner-dependent revenues — Royalty revenue depends on sales by collaboration partners; a change in partner strategy or regulatory hurdles could materially reduce collections.
• Supply chain risk for Captisol — Captisol is sourced from a sole supplier; a supply interruption could impair sales and related royalty streams.
• Partner insolvency — Collaboration partners may become insolvent, jeopardizing expected royalty and milestone payments.
• Intellectual property challenges — Third-party IP rights or inadequate IP protection could prevent or limit development/commercialization of partnered products, reducing future royalties.

Outlook

Management raised the low end of 2026 adjusted EPS guidance and maintained revenue guidance, citing strong royalty momentum and the XOMA acquisition for a strong second half. The company expects to use remaining proceeds from the 2031 notes for general corporate purposes, including investing in complementary businesses. No specific numeric outlook beyond guidance was provided in the excerpts.